Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024.
"Despite the availability of numerous immunosuppressive therapies, the unmet medical need remains high in lung transplantation, which has a 5-year mortality of approximately 50%. New targeted therapeutic approaches are clearly needed that can optimize immunosuppression in the lung while avoiding the dose-limiting toxicities associated with systemically administered immunosuppressive therapies," said Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital and Lead Principal Investigator of the Phase 2 TFF TAC trial. "Initial data from the ongoing Phase 2 study suggest that TFF TAC, which delivers tacrolimus directly to the lungs, may represent a viable approach in achieving this desired balance, and I look forward to presenting initial data from the Phase 2 trial at the upcoming ISHLT 2024 meeting."
Posted In: TFFP